Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | PER2 | O15055 | 1/20 | 0.40 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.40 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596549 | 0.81 | RAB9A (0.40) | RAB9AALDH1A1XBP1HTTSIGMAR1 | |
| SCHEMBL18497279 | 0.80 | ACHE (0.40) | TRPM8 | |
| SCHEMBL1827400 | 0.80 | SRD5A1 (0.40) | — | |
| SCHEMBL193594 | 0.80 | RAB9A (0.58) | RAB9AALDH1A1XBP1HTTTRPM8 | |
| SCHEMBL193593 | 0.80 | RAB9A (0.58) | RAB9AALDH1A1XBP1HTTTRPM8 | |
| SCHEMBL2576333 | 0.79 | MAPT (0.39) | RAB9A | |
| SCHEMBL2283972 | 0.78 | PYGL (0.43) | MAPK14 | |
| SCHEMBL2281716 | 0.78 | PYGL (0.43) | MAPK14 | |
| SCHEMBL1665427 | 0.78 | TRPM8 (0.49) | RAB9AALDH1A1XBP1HTTTRPM8 | |
| SCHEMBL2284193 | 0.77 | SCN9A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2402334-A1 | Inhibitors of E1 Activating Enzymes | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | RAB9A 2706/4885ALDH1A1 987/4885XBP1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.